New York, USA, April 28, 2026 (GLOBE NEWSWIRE)-- Global AAV Vector Manufacturing Market Gearing Up for Outstanding Expansion at a CAGR of ~22% by 2034 | DelveInsight The AAV vector manufacturing ...
Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter ...
Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
University of Zurich scientists demonstrated that they could reassemble and express large genes using a new dual adeno-associated viral (AAV) vector technology that depends on mRNA trans-splicing.
Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...
Researchers have developed an engineered adeno-associated virus (AAV) vector that yields high transduction of brain vascular pericytes and smooth muscle cells. The study describing the ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
What Are AAV Vector-Based Therapies? Gene therapies are groundbreaking approaches utilizing viral and non-viral vectors. These vectors introduce therapeutic genes into patient cells to treat diseases, ...
Genethon, Ampersand Biomedicines partner to design novel AAV vectors with enhanced tissue specificity for effective tolerated gene therapies: France Saturday, May 23, 2026, 16:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results